(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing the management of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) included a discussion of the nine key panel questions specific to the mHSPC disease space. Dr. Bertrand Tombal and Dr. Nicholas James started with the results of question #12: In the majority of patients with synchronous high-volume (on conventional imaging or unequivocal on next-generation imaging) mHSPC, what is your preferred systemic treatment in addition to ADT?